Comparison of clinical and molecular characteristics by ASXL1 mutation status in primary CN-AML patients 60 years of age or older
| Variable . | ASXL1-mut (n = 38) . | ASXL1-wt (n = 182) . | P . |
|---|---|---|---|
| Age, y | .43 | ||
| Median | 68 | 69 | |
| Range | 61-83 | 60-82 | |
| Male sex, no. (%) | 24 (63) | 85 (47) | .08 |
| Race, no. (%) | .75 | ||
| White | 34 (89) | 164 (92) | |
| Nonwhite | 4 (11) | 15 (8) | |
| WBC, × 109/L | .02 | ||
| Median | 10.6 | 28.1 | |
| Range | 0.9-173.1 | 0.9-450.0 | |
| Percent of blood blasts | < .001 | ||
| Median | 12 | 52 | |
| Range | 0-88 | 0-99 | |
| Percent of bone marrow blasts | .04 | ||
| Median | 52 | 67 | |
| Range | 8-93 | 4-97 | |
| Hemoglobin, g/dL | .74 | ||
| Median | 9.4 | 9.4 | |
| Range | 6.0-11.7 | 5.4-15.0 | |
| Platelet count, × 109/L | .06 | ||
| Median | 85 | 65 | |
| Range | 14-510 | 4-850 | |
| FAB category, no. (%)* | — | ||
| M0 | 1 (4) | 2 (2) | |
| M1 | 2 (8) | 31 (25) | |
| M2 | 12 (50) | 36 (29) | |
| M4 | 6 (25) | 27 (22) | |
| M5 | 3 (13) | 24 (20) | |
| M6 | 0 (0) | 3 (2) | |
| Extramedullary involvement, no. (%) | 7 (18) | 42 (23) | .67 |
| NPM1, no. (%) | < .001 | ||
| Mutated | 2 (5) | 125 (69) | |
| Wild-type | 36 (95) | 57 (31) | |
| FLT3-ITD, no. (%) | .002 | ||
| Positive | 4 (11) | 66 (36) | |
| Negative | 34 (89) | 116 (64) | |
| CEBPA, no. (%) | .01 | ||
| Mutated | 10 (26) | 17 (9) | |
| Single mutated | 5 | 11 | |
| Double mutated | 5 | 6 | |
| Wild-type | 28 (74) | 165 (91) | |
| ELN genetic category, no. (%)† | .08 | ||
| Favorable | 12 (32) | 87 (48) | |
| Intermediate-I | 26 (68) | 95 (52) | |
| TET2, no. (%) | 1.0 | ||
| Mutated | 11 (29) | 55 (30) | |
| Wild-type | 27 (71) | 126 (70) | |
| IDH1, no. (%) | 1.0 | ||
| Mutated | 4 (11) | 22 (12) | |
| Wild-type | 34 (89) | 159 (88) | |
| IDH2, no. (%) | .21 | ||
| IDH2 mutated | 12 (32) | 39 (22) | |
| Codon R140 mutation | 10 | 31 | |
| Codon R172 mutation | 2 | 8 | |
| Wild-type | 26 (68) | 142 (78) | |
| FLT3-TKD, no. (%) | .54 | ||
| Present | 2 (5) | 18 (10) | |
| Absent | 36 (95) | 164 (90) | |
| WT1, no. (%) | .48 | ||
| Mutated | 1 (3) | 14 (8) | |
| Wild-type | 37 (97) | 168 (92) | |
| MLL-PTD, no. (%) | .28 | ||
| Present | 4 (11) | 9 (6) | |
| Absent | 31 (89) | 139 (94) |
| Variable . | ASXL1-mut (n = 38) . | ASXL1-wt (n = 182) . | P . |
|---|---|---|---|
| Age, y | .43 | ||
| Median | 68 | 69 | |
| Range | 61-83 | 60-82 | |
| Male sex, no. (%) | 24 (63) | 85 (47) | .08 |
| Race, no. (%) | .75 | ||
| White | 34 (89) | 164 (92) | |
| Nonwhite | 4 (11) | 15 (8) | |
| WBC, × 109/L | .02 | ||
| Median | 10.6 | 28.1 | |
| Range | 0.9-173.1 | 0.9-450.0 | |
| Percent of blood blasts | < .001 | ||
| Median | 12 | 52 | |
| Range | 0-88 | 0-99 | |
| Percent of bone marrow blasts | .04 | ||
| Median | 52 | 67 | |
| Range | 8-93 | 4-97 | |
| Hemoglobin, g/dL | .74 | ||
| Median | 9.4 | 9.4 | |
| Range | 6.0-11.7 | 5.4-15.0 | |
| Platelet count, × 109/L | .06 | ||
| Median | 85 | 65 | |
| Range | 14-510 | 4-850 | |
| FAB category, no. (%)* | — | ||
| M0 | 1 (4) | 2 (2) | |
| M1 | 2 (8) | 31 (25) | |
| M2 | 12 (50) | 36 (29) | |
| M4 | 6 (25) | 27 (22) | |
| M5 | 3 (13) | 24 (20) | |
| M6 | 0 (0) | 3 (2) | |
| Extramedullary involvement, no. (%) | 7 (18) | 42 (23) | .67 |
| NPM1, no. (%) | < .001 | ||
| Mutated | 2 (5) | 125 (69) | |
| Wild-type | 36 (95) | 57 (31) | |
| FLT3-ITD, no. (%) | .002 | ||
| Positive | 4 (11) | 66 (36) | |
| Negative | 34 (89) | 116 (64) | |
| CEBPA, no. (%) | .01 | ||
| Mutated | 10 (26) | 17 (9) | |
| Single mutated | 5 | 11 | |
| Double mutated | 5 | 6 | |
| Wild-type | 28 (74) | 165 (91) | |
| ELN genetic category, no. (%)† | .08 | ||
| Favorable | 12 (32) | 87 (48) | |
| Intermediate-I | 26 (68) | 95 (52) | |
| TET2, no. (%) | 1.0 | ||
| Mutated | 11 (29) | 55 (30) | |
| Wild-type | 27 (71) | 126 (70) | |
| IDH1, no. (%) | 1.0 | ||
| Mutated | 4 (11) | 22 (12) | |
| Wild-type | 34 (89) | 159 (88) | |
| IDH2, no. (%) | .21 | ||
| IDH2 mutated | 12 (32) | 39 (22) | |
| Codon R140 mutation | 10 | 31 | |
| Codon R172 mutation | 2 | 8 | |
| Wild-type | 26 (68) | 142 (78) | |
| FLT3-TKD, no. (%) | .54 | ||
| Present | 2 (5) | 18 (10) | |
| Absent | 36 (95) | 164 (90) | |
| WT1, no. (%) | .48 | ||
| Mutated | 1 (3) | 14 (8) | |
| Wild-type | 37 (97) | 168 (92) | |
| MLL-PTD, no. (%) | .28 | ||
| Present | 4 (11) | 9 (6) | |
| Absent | 31 (89) | 139 (94) |
FAB indicates French-American-British classification; and —, not applicable.
FAB categories are centrally reviewed
Within CN-AML patients, the ELN Favorable group is defined as patients with mutated CEBPA and/or mutated NPM1 without FLT3-ITD. All remaining CN-AML patients (ie, those with wild-type CEBPA, and FLT3-ITD and/or wild-type NPM1) belong to the ELN Intermediate-I category.27